Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
JCO Global Oncology|June 15, 2021
Strengthening Pathology Capacity to Deliver Quality Cancer Care in Cities in LMICsSilvina Frech, Luis Eduardo Bravo, Ingrid Rodriguez, et al.
BMC Health Services Research|January 8, 2021
Improving evidence-based grouping of transitional care strategies in hospital implementation using statistical tools and expert reviewJing Li, Gaixin Du, Jessica Miller Clouser, et al.
BMC Health Services Research|May 21, 2021
Development and psychometric properties of surveys to assess provider perspectives on the barriers and facilitators of effective care transitionsMaurice C Johnson, Helen Liu, Joann Sorra, et al.
Breast Cancer Research and Treatment|October 24, 2018
Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence scorePiiha-Lotta Jerevall, Jane Brock, Juan Palazzo, et al.
BMC Health Services Research|August 10, 2021
Development and psychometric properties of surveys to assess patient and family caregiver experience with care transitionsJoann Sorra, Katarzyna Zebrak, Deborah Carpenter, et al.
Joint Commission Journal on Quality and Patient Safety|November 12, 2021
Effects of Different Transitional Care Strategies on Outcomes after Hospital Discharge-Trust Matters, TooJing Li, Jessica Miller Clouser, Jane Brock, et al.
Nature Communications|April 7, 2020
Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineagesJennifer M Rosenbluth, Ron C J Schackmann, G Kenneth Gray, et al.
Investigational New Drugs|July 1, 2015
Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancerSara M Tolaney, Sally Tan, Hao Guo, et al.
Journal of the American Geriatrics Society|April 4, 2017
Components of Comprehensive and Effective Transitional CareMary D Naylor, Elizabeth C Shaid, Deborah Carpenter, et al.
NPJ Breast Cancer|May 16, 2018
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancerDaniel G Stover, Carlos R Gil Del Alcazar, Jane Brock, et al.
Pageof 4